We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Virus Diagnosis Device Delivers Lab-Quality Results within Three Minutes

By LabMedica International staff writers
Posted on 03 Nov 2023
Print article
Image: The prototype LoCKAmp device uses innovative ‘lab on a chip’ technology to detect viruses (Photo courtesy of University of Bath)
Image: The prototype LoCKAmp device uses innovative ‘lab on a chip’ technology to detect viruses (Photo courtesy of University of Bath)

Researchers have developed a device capable of delivering lab-grade viral diagnostic results in just three minutes, offering a rapid and economical solution for detecting COVID-19 from nasal swabs. This technology, according to its developers, is versatile enough to be modified for identifying various pathogens, such as bacteria, and potentially even cancer.

The prototype LoCKAmp device developed by engineers at the University of Bath (Bath, UK) uses advanced 'lab on a chip' technology. The device operates by quickly releasing and amplifying genetic material from a nasal swab sample and facilitating a chemical reaction that produces a result that can be viewed through a smartphone application. The LoCKAmp device differs from the common lateral flow tests used throughout the pandemic by employing the same genetic detection methods previously reserved for laboratory-grade PCR (polymerase chain reaction) tests, delivering rapid lab-level testing to the public for the first time. A key feature of the LoCKAmp is its rapid result time, clocking in at three minutes, making it the fastest COVID-19 test reported so far.

Built using readily available parts and mass-produced circuit boards, the LoCKAmp prototype device can be manufactured quickly and cost-effectively on a large scale. This presents an efficient new tool for healthcare providers and public health authorities globally in the field of virus detection. The research team suggests that with a commercial partner experienced in design and manufacturing, the LoCKAmp could be redesigned into a compact, portable device, ideal for use in areas with limited access to healthcare. Beyond just evaluating nasal swab samples, the LoCKAmp technology also has the potential for anonymous, community-level virus monitoring by testing samples from sources such as wastewater.

“This is an amazing display of the possibilities of lab-on-a-chip technology, and given the low cost and adaptability of the technology to detect a range of conditions, a potentially highly valuable and unique tool for a range of healthcare settings,” said Dr. Despina Moschou from the University of Bath who led the research.

Related Links:
University of Bath

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
HbA1c Test
HbA1c Rapid Test
New
Benchtop Cooler
PCR-Cooler & PCR-Rack

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more